JP4722834B2 - 卵巣癌査定のための尿のメソセリン／巨核球可能化因子関連ペプチド（ｍｅｓｏｔｈｅｌｉｎ／ｍｅｇａｋａｒｙｏｃｙｔｅｐｏｔｅｎｔｉａｔｉｎｇｆａｃｔｏｒｆａｍｉｌｙｐｅｐｔｉｄｅ）の検出 - Google Patents

卵巣癌査定のための尿のメソセリン／巨核球可能化因子関連ペプチド（ｍｅｓｏｔｈｅｌｉｎ／ｍｅｇａｋａｒｙｏｃｙｔｅｐｏｔｅｎｔｉａｔｉｎｇｆａｃｔｏｒｆａｍｉｌｙｐｅｐｔｉｄｅ）の検出 Download PDF

Info

Publication number
JP4722834B2
JP4722834B2 JP2006507164A JP2006507164A JP4722834B2 JP 4722834 B2 JP4722834 B2 JP 4722834B2 JP 2006507164 A JP2006507164 A JP 2006507164A JP 2006507164 A JP2006507164 A JP 2006507164A JP 4722834 B2 JP4722834 B2 JP 4722834B2
Authority
JP
Japan
Prior art keywords
antibody
urine
peptide
mmpff
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006507164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007525643A (ja
JP2007525643A5 (enExample
Inventor
ダニエル ジェー オウシャネッスィー
ニランジャン ワイ サルデサイ
ジェニファー ボーンズ
Original Assignee
フジレビオ アメリカ インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フジレビオ アメリカ インク filed Critical フジレビオ アメリカ インク
Publication of JP2007525643A publication Critical patent/JP2007525643A/ja
Publication of JP2007525643A5 publication Critical patent/JP2007525643A5/ja
Application granted granted Critical
Publication of JP4722834B2 publication Critical patent/JP4722834B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2006507164A 2003-03-13 2004-03-15 卵巣癌査定のための尿のメソセリン／巨核球可能化因子関連ペプチド（ｍｅｓｏｔｈｅｌｉｎ／ｍｅｇａｋａｒｙｏｃｙｔｅｐｏｔｅｎｔｉａｔｉｎｇｆａｃｔｏｒｆａｍｉｌｙｐｅｐｔｉｄｅ）の検出 Expired - Lifetime JP4722834B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/388,930 US20040180387A1 (en) 2003-03-13 2003-03-13 Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US10/388,930 2003-03-13
PCT/US2004/007765 WO2004083449A2 (en) 2003-03-13 2004-03-15 Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011050083A Division JP5570029B2 (ja) 2003-03-13 2011-03-08 卵巣癌査定のための尿のメソセリン／巨核球可能化因子関連ペプチド（ｍｅｓｏｔｈｅｌｉｎ／ｍｅｇａｋａｒｙｏｃｙｔｅｐｏｔｅｎｔｉａｔｉｎｇｆａｃｔｏｒｆａｍｉｌｙｐｅｐｔｉｄｅ）の検出

Publications (3)

Publication Number Publication Date
JP2007525643A JP2007525643A (ja) 2007-09-06
JP2007525643A5 JP2007525643A5 (enExample) 2011-04-21
JP4722834B2 true JP4722834B2 (ja) 2011-07-13

Family

ID=32962160

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006507164A Expired - Lifetime JP4722834B2 (ja) 2003-03-13 2004-03-15 卵巣癌査定のための尿のメソセリン／巨核球可能化因子関連ペプチド（ｍｅｓｏｔｈｅｌｉｎ／ｍｅｇａｋａｒｙｏｃｙｔｅｐｏｔｅｎｔｉａｔｉｎｇｆａｃｔｏｒｆａｍｉｌｙｐｅｐｔｉｄｅ）の検出
JP2011050083A Expired - Lifetime JP5570029B2 (ja) 2003-03-13 2011-03-08 卵巣癌査定のための尿のメソセリン／巨核球可能化因子関連ペプチド（ｍｅｓｏｔｈｅｌｉｎ／ｍｅｇａｋａｒｙｏｃｙｔｅｐｏｔｅｎｔｉａｔｉｎｇｆａｃｔｏｒｆａｍｉｌｙｐｅｐｔｉｄｅ）の検出

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011050083A Expired - Lifetime JP5570029B2 (ja) 2003-03-13 2011-03-08 卵巣癌査定のための尿のメソセリン／巨核球可能化因子関連ペプチド（ｍｅｓｏｔｈｅｌｉｎ／ｍｅｇａｋａｒｙｏｃｙｔｅｐｏｔｅｎｔｉａｔｉｎｇｆａｃｔｏｒｆａｍｉｌｙｐｅｐｔｉｄｅ）の検出

Country Status (4)

Country Link
US (1) US20040180387A1 (enExample)
EP (2) EP2316969B1 (enExample)
JP (2) JP4722834B2 (enExample)
WO (1) WO2004083449A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072341A2 (en) * 2004-01-21 2005-08-11 Fujirebio America, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
US20060014221A1 (en) * 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
US20110003710A1 (en) * 2008-02-28 2011-01-06 John Hopkins University Selectin ligands useful in the diagnosis and treatment of cancer
JP2010014691A (ja) * 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び／又は巨核球増強因子を検出するための方法、キット、試薬及び装置
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
US8911732B2 (en) 2010-12-20 2014-12-16 Genentech, Inc. Anti-mesothelin antibodies and immunoconjugates
CN103344761A (zh) * 2013-04-23 2013-10-09 深圳市柏明胜医疗器械有限公司 一种he4量子点标记的双夹心免疫分析检测试剂盒及其应用
CN106716127B (zh) * 2014-10-02 2020-12-08 佐拉生物科学公司 用于检测卵巢癌的方法
CN106841190B (zh) * 2017-03-22 2020-07-24 西北师范大学 以TMB为显色剂的Ag+可视化检测方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5139744A (en) * 1986-03-26 1992-08-18 Beckman Instruments, Inc. Automated laboratory work station having module identification means
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2093928C (en) * 1990-10-12 2000-02-29 Mark C. Willingham Monoclonal antibodies for detection and treatment of cancer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1279731B1 (en) 1991-03-01 2007-05-30 Dyax Corporation Process for the development of binding mini-proteins
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP3328341B2 (ja) * 1991-12-27 2002-09-24 中外製薬株式会社 新規な巨核球増幅因子
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
EP0871492B1 (en) * 1996-01-05 2003-11-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Mesothelium antigen and methods and kits for targeting it
CA2369433A1 (en) * 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6770445B1 (en) * 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer

Also Published As

Publication number Publication date
HK1157821A1 (en) 2012-07-06
US20040180387A1 (en) 2004-09-16
WO2004083449A2 (en) 2004-09-30
EP2316969A1 (en) 2011-05-04
EP1611250A4 (en) 2007-04-18
JP2007525643A (ja) 2007-09-06
EP1611250A2 (en) 2006-01-04
WO2004083449A3 (en) 2005-09-15
EP2316969B1 (en) 2015-12-16
EP1611250B1 (en) 2012-12-19
JP5570029B2 (ja) 2014-08-13
JP2011174933A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
JP5570029B2 (ja) 卵巣癌査定のための尿のメソセリン／巨核球可能化因子関連ペプチド（ｍｅｓｏｔｈｅｌｉｎ／ｍｅｇａｋａｒｙｏｃｙｔｅｐｏｔｅｎｔｉａｔｉｎｇｆａｃｔｏｒｆａｍｉｌｙｐｅｐｔｉｄｅ）の検出
ES2748397T3 (es) Uso de HE4 y otros marcadores bioquímicos para la evaluación de cánceres de ovario
MX2007000383A (es) Metodos y composiciones para la deteccion de enfermedad ovarica.
WO2010102167A1 (en) Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
JP2012524521A (ja) グリコデリンモノクローナル抗体および卵巣癌の検出におけるその使用のための方法
AU2011293217A1 (en) Methods for detecting anti-HE4 antibodies and methods of diagnosis and/or prognosis of conditions associated with HE4-expressing cells
CN113287013B (zh) 溃疡性大肠炎以及原发性硬化性胆管炎的检查方法
US8110663B2 (en) Monoclonal antibodies for cartillage oligomeric matrix protein
JP2007525643A5 (enExample)
CN109517062A (zh) 能够结合linc00266-1多肽的抗体
EP1780215B1 (en) Crohn's disease antibody epitope peptide and reagent for testing crohn's disease
US20060014211A1 (en) Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
CN112415199B (zh) Cetp检测试剂在制备肺癌筛查试剂盒中的用途
US20060014221A1 (en) Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of mesothelioma
CA2486119A1 (en) Method of isolating an endothelial cell and method of donor specific crossmatching
HK1157821B (en) Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
JP2012519290A (ja) 肺の扁平上皮癌のためのマーカーとしてのセルピンｂ１３
KR20200080183A (ko) 치주질환 진단 방법, 이를 위한 조성물 및 키트
WO1997010508A1 (en) Method for the diagnosis of coeliac disease
HK1133445B (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers
HK1133445A (en) Use of he4 and other biochemical markers for assessment of endometrial and uterine cancers

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20050913

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070302

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070302

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091201

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101213

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110308

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110404

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110406

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140415

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4722834

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term